Biosimilar Retacrit debuts in USA at a substantial discount

15 November 2018
biosimilars_samples_large

After a number of setbacks on the path to market, US pharma giant Pfizer (NYSE:PFE) has announced the introduction of Retacrit (epoetin alfa-epbx) injection in the USA.

This is the first available biosimilar to Procrit (epoetin alfa) and Epogen (epoetin alfa) from Amgen (Nasdaq: AMGN) and Johnson & Johnson’s (NYSE: JNJ)in the USA, and is being made available at a substantial discount. Pfizer began shipment of Retacrit to wholesalers in the USA on November 12, 2018.

Retacrit will be introduced at a Wholesale Acquisition Cost (WAC) of $11.03 per 1,000 units/mL, which is 57.1% below the WAC of Procrit (epoetin alfa) [$25.72 per 1,000 units/mL] and 33.5% below the WAC of Epogen (epoetin alfa) [$16.58 per 1,000 units/mL], its reference product. The WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars